EE200200534A - Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat - Google Patents
Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaatInfo
- Publication number
- EE200200534A EE200200534A EEP200200534A EEP200200534A EE200200534A EE 200200534 A EE200200534 A EE 200200534A EE P200200534 A EEP200200534 A EE P200200534A EE P200200534 A EEP200200534 A EE P200200534A EE 200200534 A EE200200534 A EE 200200534A
- Authority
- EE
- Estonia
- Prior art keywords
- preparation
- torasemide
- salts
- pharmaceutical
- amorphous modification
- Prior art date
Links
- NGBFQHCMQULJNZ-UHFFFAOYSA-N Torsemide Chemical compound CC(C)NC(=O)NS(=O)(=O)C1=CN=CC=C1NC1=CC=CC(C)=C1 NGBFQHCMQULJNZ-UHFFFAOYSA-N 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 229960005461 torasemide Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Materials For Medical Uses (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HR20000162A HRP20000162B1 (en) | 2000-03-20 | 2000-03-20 | Amorphous torasemide modification |
| PCT/HR2000/000011 WO2001070694A1 (en) | 2000-03-20 | 2000-05-02 | Amorphous torasemide modification |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EE200200534A true EE200200534A (et) | 2004-04-15 |
Family
ID=10947070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EEP200200534A EE200200534A (et) | 2000-03-20 | 2000-05-02 | Torasemiidi amorfne modifikatsioon, selle valmistamine ja kasutamine soolade saamiseks ning seda sisaldav farmatseutiline preparaat |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6767917B1 (et) |
| EP (1) | EP1272470B1 (et) |
| JP (1) | JP2003528083A (et) |
| KR (1) | KR20020093847A (et) |
| CN (1) | CN1211368C (et) |
| AR (1) | AR023788A1 (et) |
| AT (1) | ATE256662T1 (et) |
| AU (1) | AU2000241348A1 (et) |
| BG (1) | BG107208A (et) |
| BR (1) | BR0017175A (et) |
| CA (1) | CA2401908A1 (et) |
| CZ (1) | CZ20023436A3 (et) |
| DE (1) | DE60007360T2 (et) |
| EA (1) | EA004950B1 (et) |
| EE (1) | EE200200534A (et) |
| ES (1) | ES2213006T3 (et) |
| GE (1) | GEP20043300B (et) |
| HR (1) | HRP20000162B1 (et) |
| HU (1) | HUP0300596A3 (et) |
| IL (1) | IL151801A0 (et) |
| IS (1) | IS6551A (et) |
| MX (1) | MXPA02009210A (et) |
| NO (1) | NO20024464L (et) |
| PL (1) | PL357154A1 (et) |
| PT (1) | PT1272470E (et) |
| SK (1) | SK15092002A3 (et) |
| WO (1) | WO2001070694A1 (et) |
| YU (1) | YU70502A (et) |
| ZA (1) | ZA200208309B (et) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI20816A (sl) * | 1999-08-11 | 2002-08-31 | Teva Pharmaceutical Industries Ltd. | Polimorfi torsemid-a |
| IN192178B (et) * | 2001-08-03 | 2004-03-06 | Ranbaxy Lab | |
| EP1668008A4 (en) | 2003-08-28 | 2009-02-25 | Nitromed Inc | NITROSED AND NITROSYLATED DIETETIC COMPOUNDS, COMPOSITIONS AND APPLICATION METHODS |
| AU2006216665A1 (en) | 2005-02-24 | 2006-08-31 | Nicox S.A. | Nitric oxide enhancing diuretic compounds, compositions and methods of use |
| CN100421662C (zh) * | 2005-11-08 | 2008-10-01 | 周卓和 | 托拉塞米分散片及其制备方法和应用 |
| CN104370805B (zh) * | 2013-08-13 | 2016-09-07 | 天津汉瑞药业有限公司 | 托拉塞米化合物 |
| CN105949115A (zh) * | 2016-05-26 | 2016-09-21 | 南京正科医药股份有限公司 | 一种新晶型托拉塞米 |
| CN115417810B (zh) * | 2022-09-22 | 2023-10-10 | 南京正科医药股份有限公司 | 一种托拉塞米晶型ⅰ的精制方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1477664A (en) | 1974-04-17 | 1977-06-22 | Christiaens Sa A | Pyridine derivatives |
| DE3529529A1 (de) * | 1985-08-17 | 1987-02-19 | Boehringer Mannheim Gmbh | Verfahren zur herstellung einer stabilen modifikation von torasemid |
| GB8816620D0 (en) | 1988-07-13 | 1988-08-17 | Lepetit Spa | Rifapentine hydrohalides |
| ES2150105T3 (es) | 1995-02-22 | 2000-11-16 | Aventis Pharma Ltd | Piretanida amorfa, polimorfos de piretanida, proceso para su preparacion y su uso. |
| IN182496B (et) | 1996-02-20 | 1999-04-17 | Reddy Research Foundation | |
| HRP980532B1 (en) | 1998-10-02 | 2005-06-30 | Pliva | Novel crystalline torasemide modification |
| US5914336A (en) * | 1998-06-02 | 1999-06-22 | Boehringer Mannheim Gmbh | Method of controlling the serum solubility of orally administered torasemide and composition relating thereto |
| SI20816A (sl) | 1999-08-11 | 2002-08-31 | Teva Pharmaceutical Industries Ltd. | Polimorfi torsemid-a |
-
2000
- 2000-03-20 HR HR20000162A patent/HRP20000162B1/xx not_active IP Right Cessation
- 2000-04-28 AR ARP000102019A patent/AR023788A1/es unknown
- 2000-05-02 BR BR0017175-1A patent/BR0017175A/pt not_active IP Right Cessation
- 2000-05-02 JP JP2001568906A patent/JP2003528083A/ja active Pending
- 2000-05-02 AT AT00920938T patent/ATE256662T1/de not_active IP Right Cessation
- 2000-05-02 MX MXPA02009210A patent/MXPA02009210A/es unknown
- 2000-05-02 EP EP00920938A patent/EP1272470B1/en not_active Expired - Lifetime
- 2000-05-02 CA CA002401908A patent/CA2401908A1/en not_active Abandoned
- 2000-05-02 SK SK1509-2002A patent/SK15092002A3/sk unknown
- 2000-05-02 ES ES00920938T patent/ES2213006T3/es not_active Expired - Lifetime
- 2000-05-02 US US10/239,024 patent/US6767917B1/en not_active Expired - Fee Related
- 2000-05-02 GE GE4937A patent/GEP20043300B/en unknown
- 2000-05-02 PT PT00920938T patent/PT1272470E/pt unknown
- 2000-05-02 WO PCT/HR2000/000011 patent/WO2001070694A1/en not_active Ceased
- 2000-05-02 EA EA200201003A patent/EA004950B1/ru not_active IP Right Cessation
- 2000-05-02 DE DE60007360T patent/DE60007360T2/de not_active Expired - Fee Related
- 2000-05-02 AU AU2000241348A patent/AU2000241348A1/en not_active Abandoned
- 2000-05-02 CN CNB008194319A patent/CN1211368C/zh not_active Expired - Fee Related
- 2000-05-02 YU YU70502A patent/YU70502A/sh unknown
- 2000-05-02 IL IL15180100A patent/IL151801A0/xx unknown
- 2000-05-02 KR KR1020027012411A patent/KR20020093847A/ko not_active Withdrawn
- 2000-05-02 PL PL00357154A patent/PL357154A1/xx not_active Application Discontinuation
- 2000-05-02 HU HU0300596A patent/HUP0300596A3/hu unknown
- 2000-05-02 EE EEP200200534A patent/EE200200534A/et unknown
- 2000-05-02 CZ CZ20023436A patent/CZ20023436A3/cs unknown
-
2002
- 2002-09-17 IS IS6551A patent/IS6551A/is unknown
- 2002-09-18 NO NO20024464A patent/NO20024464L/no not_active Application Discontinuation
- 2002-10-15 ZA ZA200208309A patent/ZA200208309B/en unknown
- 2002-10-21 BG BG107208A patent/BG107208A/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EE200300587A (et) | Vedel farmatseutiline kompositsioon, selle valmistamise meetod ja kasutamine | |
| EE200300171A (et) | Kristalliline monohüdraat, meetodid selle valmistamiseks ja selle kasutamine farmatseutilise kompositsiooni valmistamiseks | |
| EE200300236A (et) | 1,2-difenüülasetidinoonid, nende kasutamine, ravim ja selle valmistamismeetod | |
| AU2001277741A1 (en) | 2-aminopyridine compounds and use thereof as drugs | |
| NO20024175D0 (no) | Azetidinderivater, deres fremstilling og farmasöytiske forbindelser inneholdende de samme | |
| EE05183B1 (et) | Asabitsklilised hendid, nende valmistamine ja kasutamine ravimitena ning neid sisaldav farmatseutiline kompositsioon | |
| CY2012032I1 (el) | Ενωσεις 1,2-διυδροπυριδινης, διεργασια για την παρασκευη των ιδιων και χρηση εξ αυτων | |
| LTPA2014005I1 (lt) | Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas | |
| EE05232B1 (et) | Reguleeritud vabastamisega graanul, meetod selle valmistamiseks ning seda sisaldav mitmehikuline ravimvorm | |
| EE05475B1 (et) | Superantigeeni sisaldav konjugaat, konjugaadi kasutamine ja konjugaati sisaldav farmatseutiline kompositsioon | |
| HUP0303103A3 (en) | Fused pyrrolocarbazoles, pharmaceutical compositions containing them and use of the compounds | |
| EE200200484A (et) | Väikeseannuseline entekaviiripreparaat ja selle kasutamine | |
| EE200300327A (et) | Uurea derivaadid, nende valmistamismeetodid, kasutamine ja farmatseutiline kompositsioon | |
| EE03613B1 (et) | Omeprasooli naatriumisool,selle valmistamise protsess,seda sisaldav ravimkoostis ja selle kasutamine seedetrakti häirete ravimiseks | |
| EE200100391A (et) | Peptidüül-heterotsüklilised ketoonid, nende kasutamine ja farmatseutiline kompositsioon | |
| EE05286B1 (et) | Perindopriili tert-butlamiinsoola kristalliline kamma-vorm, protsess selle valmistamiseks ning seda sisaldavad farmatseutilised kompositsioonid | |
| EE05020B1 (et) | Glburiidi ravimkoostis | |
| EE200000596A (et) | Tienüülasolüülalkoksüetaanamiinderivaadid, nende ja nende soolade valmistamismeetod ja kasutamine, farmatseutiline kompositsioon ja kasutamine ning vaheühend ja selle valmistamismeetod | |
| EE200200617A (et) | (Tio)karbamiidi derivaat, seda sisaldav farmatseutiline preparaat, selle valmistamine ning kasutamine VIIa-teguri inhibiitorina | |
| EE04490B1 (et) | Ühend, selle valmistamise meetod ning kasutamine meditsiinis | |
| DE60109530D1 (de) | Amorphe Mupirocin enthaltende Arzneimittel | |
| NO326689B1 (no) | Pyrrolidinderivater, anvendelse derav, farmasøytisk preparat samt fremgangsmåte for fremstilling av forbindelsene | |
| EE200300488A (et) | Lipiiditaset alandava toimega bifenüülkarboksamiidühend, meetod selle valmistamiseks ning seda sisaldav ravimkompositsioon | |
| NO20032614D0 (no) | Farmasöytisk sammensetning med forbedret absorbabilitet | |
| EE05168B1 (et) | N-guanidinoalklamiid, meetod selle valmistamiseks, seda sisaldav farmatseutiline preparaat ning raviotstarbeline kasutamine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB1A | Change in the ownership or in the address of the owner | ||
| GB1A | Change in the ownership or in the address of the owner |